NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) and Roche Diagnostics today signed a co-marketing agreement in support of the installation by the Cogenics Division of Clinical Data, the worldwide leading pharmacogenomics and molecular biology services company, of a 454 Genome Sequencer FLX System in one of their European facilities. Cogenics plans to offer the 454 GS FLX ‘Next Generation’ sequencing technology as a fee-for-service offering to clients worldwide, with applications ranging from whole genome sequencing to genome wide expression profiling, and will collaborate with Roche to co-market the service.
